Fundraising FoxSanderling Ventures — 2020 Investments
2 investments dated 2020 · listed companies and verified rows first · show all
HCW Biologics is a clinical-stage biopharmaceutical company developing fusion immunotherapeutics as first-in-class immunotherapies for autoimmune diseases, cancer, and senescence-associated dysplasia.
BiotechHealthtechLongevityMiramar, US
Hing C. Wong(Executive Officer, Director)Hing W.(Founder)inLee Flowers(Executive Officer)Rebecca Byam(Executive Officer)inPeter Rhode(Executive Officer)inPeter Sun(Director)
Board seatFred Middleton· per SEC Form D · $16M raise · filed Oct 2020
Co-investorsDeepWork Capital
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.